本文選題：PAX2 + C-MYC　； 參考：《右江民族醫(yī)學(xué)院》2017年碩士論文

【摘要】：目的:探討PAX2與C-MYC在子宮內(nèi)膜癌中發(fā)生發(fā)展的作用,進(jìn)一步分析子宮內(nèi)膜癌中PAX2及C-MYC表達(dá)與臨床病理參數(shù)的關(guān)系,為子宮內(nèi)膜癌機(jī)制研究和臨床早期診斷提供新的思路。方法:收集2014年10月至2016年10月右江民族醫(yī)學(xué)院附屬醫(yī)院和附屬河池醫(yī)院手術(shù)切除子宮內(nèi)膜癌組織60例、不典型增生組織35例、正常子宮內(nèi)膜組織35例;采用免疫組化(IHC)檢測(cè)PAX2及C-MYC在三種不同子宮內(nèi)膜中蛋白表達(dá)情況;從以上標(biāo)本中留取新鮮子宮內(nèi)膜癌組織30例、不典型增生組織12例、正常子宮內(nèi)膜組織15例;應(yīng)用實(shí)時(shí)熒光定量聚合酶鏈反應(yīng)(Quantitative Real-time PCR,Q-PCR)檢測(cè)PAX2與C-MYC m RNA在子宮內(nèi)膜癌、不典型增生內(nèi)膜及正常子宮內(nèi)膜組織中表達(dá)。所有數(shù)據(jù)采用SPSS17軟件進(jìn)行分析,以P0.05認(rèn)為具有統(tǒng)計(jì)學(xué)意義。結(jié)果:(1)免疫組化(IHC):PAX2在正常子宮內(nèi)膜組、不典型子宮內(nèi)膜組、子宮內(nèi)膜癌組陽性表達(dá)率分別為74.29%,48.57%,43.3%,三組之間陽性表達(dá)率差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。PAX2在正常子宮內(nèi)膜組陽性率高于不典型增生組(P0.05)和子宮內(nèi)膜癌組(P0.01);子宮內(nèi)膜癌組陽性表達(dá)率低于不典型增生組,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。PAX2蛋白表達(dá)與子宮內(nèi)膜癌組織的病理分化程度(P0.05)、肌層浸潤(rùn)深度相關(guān)(P0.05),與淋巴結(jié)轉(zhuǎn)移、臨床分期、年齡、病理分型無關(guān)(P0.05)。C-MYC蛋白在正常子宮內(nèi)膜組、不典型增生組、子宮內(nèi)膜癌組陽性表達(dá)率分別為17.14%,40.0%,66.67%,三組間陽性表達(dá)率差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。C-MYC在子宮內(nèi)膜癌組中的陽性表達(dá)率高于正常內(nèi)膜組(P0.01)和不典型增生內(nèi)膜組(P0.05),不典型增生內(nèi)膜組中陽性率高于正常內(nèi)膜組(P0.01)。C-MYC蛋白水平表達(dá)與子宮內(nèi)膜癌患者的病理分化(P0.05)、手術(shù)-臨床分期(P0.05)密切相關(guān);與肌層浸潤(rùn)深度、淋巴結(jié)轉(zhuǎn)移、年齡、病理分型無關(guān)(P0.05)。(2)實(shí)時(shí)熒光定量PCR(Q-PCR):PAX2 mRNA在不同子宮內(nèi)膜組織中表達(dá)量總體有差異(P0.01)。PAX2mRNA在子宮內(nèi)膜癌組中表達(dá)水平低于正常子宮內(nèi)膜對(duì)照組(P0.01);不典型增生組PAX2 mRNA低于正常子宮內(nèi)膜組(P0.01);子宮內(nèi)膜癌組低于不典型增生內(nèi)膜組(P0.05)。C-MYC mRNA在不同子宮內(nèi)膜組織中表達(dá)水平總體有差異(P0.001)。C-MYC m RNA在正常子宮內(nèi)膜組表達(dá)水平高于子宮內(nèi)膜癌組(P0.01)、不典型增生內(nèi)膜組(P0.01),子宮內(nèi)膜癌組中的mRNA表達(dá)高于不典型增生內(nèi)膜組(P0.01)。結(jié)論:(1)PAX2在不典型增生組織、子宮內(nèi)膜癌組織中的表達(dá)低于正常子宮內(nèi)膜組織,提示PAX2表達(dá)下調(diào)可能是子宮內(nèi)膜不良病變的早期事件。(2)C-MYC在子宮內(nèi)膜癌組織中表達(dá)上調(diào),可能促進(jìn)了子宮內(nèi)膜癌的發(fā)生發(fā)展,C-MYC有可能成為子宮內(nèi)膜癌潛在的診斷和治療靶點(diǎn)。
[Abstract]:Objective: to investigate the role of PAX2 and C-MYC in the occurrence and development of endometrial carcinoma, and to further analyze the relationship between the expression of PAX2 and C-MYC and clinicopathological parameters in endometrial carcinoma, so as to provide a new idea for the study of mechanism and early clinical diagnosis of endometrial carcinoma. Methods: from October 2014 to October 2016, 60 cases of endometrial carcinoma, 35 cases of atypical hyperplasia and 35 cases of normal endometrium were collected from affiliated Hospital and affiliated Hechi Hospital of Youjiang National Medical College. The expression of PAX2 and C-MYC in three kinds of endometrium were detected by immunohistochemistry, 30 cases of fresh endometrial carcinoma, 12 cases of atypical hyperplasia and 15 cases of normal endometrium were collected from above samples. The expression of PAX2 and C-MYC m RNA in endometrial carcinoma, atypical hyperplasia and normal endometrium was detected by real-time quantitative Real-time PCR Q-PCR. All the data were analyzed by SPSS17 software, and P0.05 was considered statistically significant. Results in the normal endometrium group and the atypical endometrium group, the immunohistochemical staining showed that IHC: PAX2 was found in the normal endometrium group and the atypical endometrium group. The positive rate of positive expression in endometrial carcinoma group was 74.29 and 48.57 and 43.3 respectively. The positive expression rate of P0.05U. PAX2 in normal endometrium group was significantly higher than that in atypical hyperplasia group (P0.05) and endometrial carcinoma group (P0.01a). The expression rate was lower than that in atypical hyperplasia group. There was no significant difference between the expression of P0.05, PAX2 protein and the degree of pathological differentiation of endometrial carcinoma. The depth of myometrium invasion was correlated with lymph node metastasis, clinical stage, age and pathological classification. There was no significant difference between P0.05 and C-MYC protein in normal endometrium. Atypical hyperplasia group, The positive expression rates of P0.05, C-MYC in endometrial carcinoma group were significantly higher than those in normal endometrial carcinoma group (P 0.01) and atypical hyperplasia endometrium group (P 0.05%, P 0.05%). The positive rate in endometrial group was higher than that in normal endometrium group. The expression of C-MYC protein was closely related to the pathological differentiation of endometrial carcinoma patients (P0.05, operation-clinical stage, P0.05). Depth of myometrial invasion, lymph node metastasis, age, The expression of real-time quantitative PCR(Q-PCR):PAX2 mRNA in different endometrial tissues was lower than that in normal endometrial carcinoma group (P 0.01) and PAX2 mRNA in atypical hyperplasia group was lower than that in normal endometrium control group (P 0.01), while the expression of P0.01 + PAX2 mRNA in endometrial carcinoma group was lower than that in normal endometrial carcinoma group (P < 0.05), while that in atypical hyperplasia group was lower than that in normal endometrial tissue. The expression of P0. 05 mRNA in endometrial carcinoma group was lower than that in atypical hyperplasia endometrium group. There was a general difference in the expression level of P0. 001. C-MYC m RNA in different endometrial tissues. The expression level of C-MYC m RNA in normal endometrium group was higher than that in endometrial carcinoma group (P0. 01). The expression of mRNA in endometrial carcinoma group was higher than that in atypical hyperplasia group. Conclusion the expression of PAX2 in atypical hyperplasia and endometrial carcinoma is lower than that in normal endometrial tissue, suggesting that the down-regulation of PAX2 expression may be an early event of adverse endometrial lesions. C-MYC may be a potential target for the diagnosis and treatment of endometrial carcinoma.
【學(xué)位授予單位】：右江民族醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 Ferenc Sipos;Gábor Firneisz;Gy?rgyi M?zes;;Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases[J];World Journal of Gastroenterology;2016年35期

2 鄒治銘;郭華雄;;C-myc在腫瘤中作用的研究進(jìn)展[J];現(xiàn)代醫(yī)學(xué);2016年07期

3 陳晨;郭遂群;;子宮內(nèi)膜癌組織中DAPK3和c-Myc的表達(dá)及其與患者預(yù)后的關(guān)系[J];南方醫(yī)科大學(xué)學(xué)報(bào);2016年06期

4 李麗;吳玉斌;徐海生;王長(zhǎng)山;;沉默PAX2基因?qū)δI間質(zhì)纖維化大鼠的影響[J];中國(guó)當(dāng)代兒科雜志;2016年06期

5 宋春麗;呼君瑜;李美艷;田芬;王菊榮;焦茹;劉平;;FHIT、C-myc在宮頸癌中的表達(dá)及其與高危型HPV感染的相關(guān)性[J];中國(guó)腫瘤;2016年05期

6 張盼;寇瑤;李國(guó)清;杜柏均;邵金輝;田靜;;PAX6基因突變與先天性無虹膜癥[J];基因組學(xué)與應(yīng)用生物學(xué);2016年03期

7 王亞勤;劉翔;吳晨;唐義虎;吳延虎;;c-Myc基因在人非小細(xì)胞肺癌中的表達(dá)及基因沉默抑制H1299細(xì)胞效果的實(shí)驗(yàn)研究[J];南京醫(yī)科大學(xué)學(xué)報(bào)(自然科學(xué)版);2016年02期

8 劉偉;孫志強(qiáng);謝紅衛(wèi);;基因組織特異性相關(guān)研究進(jìn)展[J];生物化學(xué)與生物物理進(jìn)展;2016年01期

9 袁雪芹;張廷國(guó);荊福祥;李亞楠;張冰;;四硝酸戊赤蘚醇5與配對(duì)盒基因在子宮內(nèi)膜癌及子宮內(nèi)膜上皮內(nèi)瘤變中的臨床表達(dá)研究[J];中華醫(yī)院感染學(xué)雜志;2016年02期

10 Sherri Rennoll;Gregory Yochum;;Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer[J];World Journal of Biological Chemistry;2015年04期

相關(guān)博士學(xué)位論文 前5條

1 張英蘭;子宮內(nèi)膜癌患者生存預(yù)后分析及早期篩查[D];北京協(xié)和醫(yī)學(xué)院;2016年

2 陳紅漫;Wnt10a/Wnt10b及其Wnt/β-catenin通路在子宮內(nèi)膜癌中的作用研究[D];天津醫(yī)科大學(xué);2014年

3 紀(jì)曉惠;PAX2、AIB1在乳腺癌組織的表達(dá)及其在TAM耐藥機(jī)制中作用的研究[D];河北醫(yī)科大學(xué);2014年

4 張昌文;ROCK-c-Myc通路促進(jìn)腫瘤增殖的分子機(jī)制研究[D];天津醫(yī)科大學(xué);2012年

5 朱翠平;PAX2在人發(fā)育腎和病理腎表達(dá)的相關(guān)研究[D];中南大學(xué);2003年

相關(guān)碩士學(xué)位論文 前3條

1 張燕;PAX2及AIB1基因在乳腺癌他莫昔芬耐藥機(jī)制中的作用的實(shí)驗(yàn)研究[D];河北醫(yī)科大學(xué);2014年

2 賈楠;PAX2在子宮內(nèi)膜癌中的表達(dá)及其DNA甲基化調(diào)控[D];復(fù)旦大學(xué);2013年

3 鄭瀊冰;原發(fā)性膀胱輸尿管反流Pax2基因啟動(dòng)子DNA甲基化狀態(tài)研究[D];復(fù)旦大學(xué);2012年

，

本文編號(hào)：1912106